507 results on '"Loteprednol Etabonate"'
Search Results
2. The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
3. The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
4. Sustained Release of Ciprofloxacin Hydrochloride and Loteprednol Etabonate from Ophthalmic Ocuserts for Treatment of Bacterial Conjunctivitis.
5. Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
6. Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates.
7. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application.
8. Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (CLEAN)
9. FORMULATION, DEVELOPMENT, AND EVALUATION OF OCUSERTS FOR QUINOLONE ANTIBIOTICS.
10. Application of Ratio Spectra Derivative Method for Simultaneous Estimation of Moxifloxacin Hydrochloride and Loteprednol Etabonate from Ophthalmic Formulation.
11. Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
12. Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
13. DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
14. Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis.
15. Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops.
16. Loteprednol vs. Prednisolone and Fluorometholone
17. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (STRIDE 1)
18. Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)
19. LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
20. Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (Maui)
21. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (Kauai)
22. Loteprednol-Loaded Nanoformulations for Corneal Delivery by Quality-by-Design Concepts: Optimization, Characterization, and Anti-inflammatory Activity.
23. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application
24. Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (STRIDE 2)
25. Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (Molokini)
26. Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
27. Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
28. Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
29. Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
30. A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
31. Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
32. Comparison of ophthalmic loteprednol etabonate and prednisolone acetate effects on adrenocortical response to ACTH in dogs.
33. Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
34. Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
35. Efficacy of Loteprednol Ointment Following Eyelid Surgery
36. Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
37. Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
38. Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
39. Development of lipid nanoparticles for transdermal loteprednol etabonate delivery.
40. Formulation and evaluation of in situ ophthalmic gel of loteprednol etabonate
41. Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
42. Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
43. A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis
44. Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
45. Validated High Performance Liquid Chromatography Method for the Quantification of Loteprednol Etabonate in Self Micro Emulsifying Drug Delivery Systems.
46. Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%.
47. Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.
48. Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis (ZvL)
49. Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
50. Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.